{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:35:36Z","timestamp":1773160536862,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T00:00:00Z","timestamp":1356912000000},"content-version":"vor","delay-in-days":2921,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obesity Research"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Objective:<\/jats:italic> This study was designed to examine whether prior authorization for insurer reimbursement of weight loss medication affects compliance with taking sibutramine or adherence to a medical weight control program. The underlying hypothesis is that physician advocacy through prior authorization increases patient compliance and treatment outcomes.<\/jats:p><jats:p><jats:italic>Research Methods and Procedures:<\/jats:italic> A retrospective review was conducted of 22 subjects who had received a prescription for sibutramine that was reimbursed through their health insurer by prior authorization (PAR) and compared them with 47 randomly selected subjects who were also prescribed sibutramine but did not receive reimbursement (non\u2010PAR). Outcome measures included the percentage weight lost, visits to the clinic, and number of prescriptions received at 3, 6, 9, and 12 months.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic> The proportion of subjects remaining in the clinic program, the number of clinic visits made, the number of prescriptions received, and the amount of weight lost were all significantly greater among PAR subjects than among non\u2010PAR subjects. PAR subjects used the medication 37% longer by month 6 (2.43 vs. 1.52 prescriptions; <jats:italic>p<\/jats:italic> &lt; 0.02), visited the clinic 44% more often (72.5 vs. 40.5 visits in 12 months; <jats:italic>p<\/jats:italic> &lt; 0.0006), and achieved 38% better maximal weight loss (16% vs. 9.9% at 6 months; <jats:italic>p<\/jats:italic> &lt; 0.49) than non\u2010PAR subjects.<\/jats:p><jats:p><jats:italic>Discussion:<\/jats:italic> This study suggests that, when those medications are not included on a health insurer's formulary, the use of the prior authorization process may improve both medication and behavioral compliance.<\/jats:p>","DOI":"10.1038\/oby.2005.11","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T21:23:15Z","timestamp":1208812995000},"page":"86-92","source":"Crossref","is-referenced-by-count":6,"title":["Does Prior Authorization of Sibutramine Improve Medication Compliance or Weight Loss?"],"prefix":"10.1002","volume":"13","author":[{"given":"Joseph A.","family":"Risser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Vash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurline","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(91)90649-C"},{"key":"e_1_2_6_3_1","first-page":"266","article-title":"Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases","volume":"3","author":"Sclar D. A.","year":"1994","journal-title":"Infect Agents Dis"},{"key":"e_1_2_6_4_1","first-page":"481","article-title":"Compliance with chemotherapy in childhood leukaemia in Africa","volume":"75","author":"MacDougall L. G.","year":"1989","journal-title":"S Afr Med J"},{"key":"e_1_2_6_5_1","first-page":"147","article-title":"Why is the treatment of cancer more successful than that of obesity?","volume":"24","author":"Berry E. M.","year":"1996","journal-title":"Publ Health Rev"},{"key":"e_1_2_6_6_1","first-page":"54","article-title":"Compliance and refill pattern behavior with HMG\u2010CoA reductase inhibitors after acute myocardial infarction","volume":"15","author":"Coombs J. H.","year":"2002","journal-title":"Manag Care Interface"},{"key":"e_1_2_6_7_1","first-page":"1","article-title":"DTC\u2010advertised drugs are more likely to be subject to PAR","volume":"3","year":"2002","journal-title":"Drug Cost Manag Rep"},{"key":"e_1_2_6_8_1","first-page":"D2","article-title":"Drug prices far outpace inflation: report by consumer group highlights cost pressures faced by senior citizens","author":"Lueck S.","year":"2003","journal-title":"Wall Street J (Eastern ed)"},{"key":"e_1_2_6_9_1","first-page":"2","article-title":"Senate votes to help states get Rx discounts","volume":"56","year":"2002","journal-title":"Mede Health"},{"key":"e_1_2_6_10_1","first-page":"405","article-title":"How does directto\u2010consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA","volume":"169","author":"Mintzes B.","year":"2003","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801969"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(67)90027-7"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80110-7"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00709.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.89.10.1536"},{"key":"e_1_2_6_16_1","first-page":"623","article-title":"Short communication: a ten\u2010year follow\u2010up of weight change in severely obese subjects treated in a combined behavioural modification programme","volume":"16","author":"Bj\u00f6rvell H.","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.14.1733"}],"container-title":["Obesity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2005.11","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/oby.2005.11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:56:53Z","timestamp":1697569013000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/oby.2005.11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1038\/oby.2005.11"],"URL":"https:\/\/doi.org\/10.1038\/oby.2005.11","archive":["Portico"],"relation":{},"ISSN":["1071-7323","1550-8528"],"issn-type":[{"value":"1071-7323","type":"print"},{"value":"1550-8528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}